Filing Flows

Filing Flows › Kymera Therapeutics (KYMR) › Next earnings date

Kymera Therapeutics (KYMR) earnings: missed the estimate

Kymera Therapeutics (KYMR) reported on Oct 29, 2026 and missed the EPS estimate: −$1.32 against −$1.27 (-4.3%). It beat the EPS estimate in 40% of the quarters on record.

Last result−4.3% vs estimate
Beat rate40%

The last report

Kymera Therapeutics reported revenue of $65.0M for the second quarter 2026 (+466% Y/Y), net loss $61.2M. How it makes money → · Every quarter →

Kymera Therapeutics: EPS against the estimate, last 5 reportsKymera Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.78−$0.94Nov 25−$0.77−$0.98Feb 26−$0.86−$0.71Apr 26−$0.74−$0.62Aug 26−$1.27−$1.32Oct 26
Latest (Oct 26): Estimate −$1.27, Reported −$1.32.

Kymera Therapeutics' latest quarter

Kymera Therapeutics, Q2 2026: revenue $65.0M (+466% year over year), operating margin -116.3%, net loss $61.2M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.

Questions

Did Kymera Therapeutics beat earnings?

Kymera Therapeutics (KYMR) reported on Oct 29, 2026 and missed the EPS estimate: −$1.32 against −$1.27 (-4.3%).

When does KYMR report earnings?

The next date is not set yet.

Does Kymera Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.